The Cuban biopharmaceutical industry in the fight against the COVID-19 pandemic

Authors

  • Eduardo Martínez Díaz BioCubaFarma
  • Rolando Pérez Rodríguez BioCubaFarma
  • Luis Herrera Martínez
  • Agustín Lage Dávila
  • Lila Castellanos Serra

Keywords:

coronavirus, pandemia, Cuba, biopharmaceutical industry, interferons, peptides, monoclonal antibodies, COVID-19

Abstract

The new coronavirus pandemic has challenged the capacity of health systems in most countries. Cuba's strategy has recently been analyzed in an article published by President Miguel Díaz-Canel and Prof. Jorge Núñez (http://www.revistaccuba.cu/index.php/revacc/article/view/881). A component of this strategy is the cuban biopharmaceutical industry. The drug coverage of the protocol established by the Ministry of Public Health for the treatment of this disease was guaranteed. Several products under development were quickly repositioned for use on the COVID-19. Biopharmaceuticals as Nasalferon, Biomodulin T and Hebertrans have been used for the prevention of infection by the SARS CoV-2 virus in risk groups; Heberon and Heberferon were administered as antiviral treatments, while Jusvinza and Itolizumab were used to stop the hyperinflammatory reaction. Biotechnology products have contributed to the reduction of seriously and critically ill patients (<7 %) and to the reduction of mortality (0,8/100 000) due to this disease, approximately 10 times lower than the world rate. The project portfolio includes other antiviral and immunomodulatory biologics, diagnostic reagent kits, products of natural origin, and medical equipments. Several vaccine candidates for the induction of specific immunity are under development, which should contribute to the definitive control of this disease in Cuba.

Downloads

Download data is not yet available.

Downloads

Published

2020-08-09

How to Cite

Martínez Díaz, E., Pérez Rodríguez, R., Herrera Martínez, L., Lage Dávila, A., & Castellanos Serra, L. (2020). The Cuban biopharmaceutical industry in the fight against the COVID-19 pandemic. Anales De La Academia De Ciencias De Cuba, 10(2), e906. Retrieved from https://revistaccuba.sld.cu/index.php/revacc/article/view/906

Issue

Vol. 10 No. 2 (2020): mayo-agosto (especial COVID-19)

Section

Contribuciones especiales

License

The journal Anales de la Academia de Ciencias de Cuba protects copyright, and operates with a Creative Commons License 4.0 (Creative Commons Attribution-NonCommercial License 4.0). By publishing in it, authors allow themselves to copy, reproduce, distribute, publicly communicate their work and generate derivative works, as long as the original author is cited and acknowledged. They do not allow, however, the use of the original work for commercial or lucrative purposes.

The authors authorize the publication of their writings, retaining the authorship rights, and assigning and transferring to the magazine all the rights protected by the intellectual property laws that govern in Cuba, which imply editing to disseminate the work.

Authors may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with recognition of having been first published in this journal.

To learn more, see https://creativecommons.org